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Summary Purpose BI 831266 is a potent, selective, low-
molecular-weight inhibitor of Aurora kinase B. This trial
aimed to determine the maximum tolerated dose (MTD) of
BI 831266 in patients with advanced solid tumors
(NCT00756223; EudraCT 2008-001631-36; 1257.1).
Methods BI 831266 (4–130 mg) was administered over 24 h
on days 1 and 15 of a 4-week schedule. A modified 3+3 dose-
escalation design was utilized to evaluate the MTD. Safety,
pharmacokinetics, pharmacodynamics, objective response
rate, progression-free survival (PFS) and exploratory bio-
markers were secondary endpoints. Results Twenty-five pa-
tients received BI 831266. The most frequent tumor type was
colorectal cancer (48 %). One patient (130 mg) experienced a
dose-limiting toxicity of grade 3 febrile neutropenia. The trial
was prematurely terminated (sponsor decision) without fur-
ther dose-escalation. The most frequent treatment-related ad-
verse events (AEs) were fatigue (20 %), neutropenia, alopecia
(16 % each), anemia, dry skin, and nausea (12 % each).
Treatment-related grade ≥3 AEs were neutropenia (12 %),
anemia (8 %), and febrile neutropenia (4 %); 15 patients
experienced serious AEs. High variability in the pharmacoki-
netic profiles precluded definitive pharmacokinetic conclu-
sions. Exploratory biomarker determination revealed consis-
tency with the mode of action as an Aurora kinase B inhibitor.
One patient (4 %; 32 mg) with cervical cancer demonstrated a
confirmed partial response (duration 141 days, PFS 414 days).
Four patients had stable disease. Conclusion The MTD of BI
831266 was not reached because of early trial termination. BI
831266 demonstrated a generally manageable safety profile
and signs of antitumor activity in some patients’ solid tumors.
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Introduction
Aurora kinases comprise a family of 3 nuclear serine/
threonine kinases (Aurora kinases A, B, and C) that play
important roles in maintaining the fidelity of mitosis and
genetic stability of cells [1, 2]. Aurora kinase A is involved
in mitotic entry, separation of centriole pairs, bipolar spindle
assembly, alignment of metaphase, and completion of cytoki-
nesis [1–4]. Aurora kinase B, previously known as AIM-1,
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regulates chromosomal orientation, chromosome condensa-
tion, spindle assembly, and cytokinesis [1, 2, 5]. It also plays
a direct role in the phosphorylation of histone H3, which is
thought to be principally linked to the initiation of cell division
[6, 7] and to chromosome instability and carcinogenesis [8].
While the role of Aurora kinase C is less well characterized,
Aurora kinases A and B are known to be involved in tumor-
igenesis [1, 2]. For example, overexpression of Aurora kinase
B induces metastasis after implantation of tumors in nude
mice [8]. Furthermore, overexpression of Aurora kinase B
has been associated with poor outcome in a variety of tumors
including glioblastoma, thyroid, and colon cancers [9–11].
The essential functions of Aurora kinases, along with their
aberrant expression across a range of tumor types, has resulted
in numerous small molecule inhibitors currently being inves-
tigated as potential therapies for solid and hematologic tumors
[1, 2]. One of these agents is BI 831266, a potent and selective
low-molecular-weight inhibitor of Aurora kinase B. Preclini-
cal studies show that BI 831266 inhibits the proliferation of
human non-small cell lung cancer (NSCLC), pancreatic can-
cer, and prostate cancer cell lines. Furthermore, in murine
xenograft tumor models (HCT 116 colon carcinoma, BxPC3
pancreatic adenocarcinoma, and NCI-H460 NSCLC), a 24-h
continuous infusion of BI 831266 resulted in tumor regression
and growth inhibition (data on file, Boehringer Ingelheim).
Here, we report the results from a multicentric, phase 1 trial
of single-agent BI 831266. The purpose of this study was to
determine the maximum tolerated dose (MTD) of BI 831266
administered to patients with a range of advanced solid tu-
mors, and to assess the safety and tolerability of the com-
pound. The pharmacokinetic (PK) and pharmacodynamic
profiles and the clinical antitumor activity of BI 831266 were
also investigated. In an exploratory approach, the role of
inhibiting the phosphorylation of histone H3 in the skin and
caspase cleaved fragment of cytokeratin-18 (CK-18) in plas-
ma were investigated as potential biomarkers. Furthermore, a
potential dependence of exposure to BI 831266 on endoge-




Patients ≥18 years of age with advanced, non-resectable and/
or metastatic solid malignant tumors, and a life expectancy of
≥3 months were eligible for inclusion in this study. Patients
had failed conventional treatment, were not amenable to
established treatment options, or there was no therapy of
proven efficacy available. Other eligibility criteria included:
Eastern Cooperative Oncology Group performance status ≤2;
recovery from toxicities from previous treatments to Common
Terminology Criteria for Adverse Events (CTCAE) grade ≤1;
adequate bone marrow, liver, and renal function (absolute
neutrophil count ≥1500/mm3, platelet count ≥100,000/mm3,
bilirubin ≤1.5 mg/dL [≤26 μmol/L, SI unit equivalent], aspar-
tate aminotransferase and/or alanine aminotransferase ≤2.5
times the upper limit of normal; if related to liver metastases,
≤5 times the upper limit of normal, serum creatinine ≤1.5 mg/
dL [≤132 μmol/L, SI unit equivalent]); no chemotherapy,
radiotherapy, immunotherapy, hormone therapy, or investiga-
tional therapy within 2 weeks prior to the start of treatment
with the trial drug; no symptomatic brain metastases,
leptomeningeal disease, or second malignancy requiring ther-
apy; and no serious illness or concomitant disease that could
potentially compromise patient safety (including clinically
significant cardiovascular disease and/or a left ventricular
ejection fraction <50 %). Also, it was required that patients
had a secure central venous access.
During the study, treatment with corticosteroids was per-
mitted. Use of growth factors, such as granulocyte colony
stimulating factor, was also allowed for treatment of
prolonged hematotoxicity at the investigator’s discretion, but
not in cycle 1 of treatment unless medically necessary. Ongo-
ing treatment with bisphosphonates or gonadotropin-releasing
hormone analogs for prostate cancer could be continued in the
trial, and concomitant therapies to provide adequate care were
given as deemed clinically necessary.
All patients were required to provide written informed
consent consistent with International Conference on Harmo-
nization–Good Clinical Practice guidelines and local
legislation.
Study design and endpoints
This was an open-label, phase 1, dose-escalation trial of BI
831266 in patients with advanced solid tumors conducted at 3
sites in Austria (NCT00756223; EudraCT 2008-001631-36;
1257.1). The trial was conducted in accordance with the
principles laid down by the Declaration of Helsinki and ap-
proved by the Independent Ethics Committees and/or Institu-
tional Review Boards of the participating centers.
A modified 3+3 dose-escalation design was used to eval-
uate the MTD of BI 831266, which was administered by
intravenous infusion over 24 h (via central venous access)
on days 1 and 15 of a 4-week schedule. Initially, 2 treatment
schedules had been planned: a 4-week schedule and a 3-week
schedule (day 1, every 3 weeks). After the MTD for the 4-
week schedule had been established, recruitment to determine
the MTD of BI 831266 on a 3-week schedule was to be
initiated, with dose tiers starting at the MTD determined in
the 4-week schedule. However, for reasons stated in the Re-
sults section and presented in detail in the Discussion, the 3-
week schedule was not started.
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Cohorts of 3–6 patients were enrolled sequentially into
escalating dose tiers of BI 831266. The MTD was defined as
the highest dose of BI 831266 at which no more than 1 of 6
patients experienced a dose-limiting toxicity (DLT) during the
first cycle of treatment. Upon determination of the MTD,
entry of additional patients at this dose level, in the form of
an expansion cohort, was planned to obtain additional safety
data.
The safe starting dose was calculated based on the FDA
guidance for starting dose selection for a cytotoxic agent in
cancer patients. Based on the data from the 3-cycle toxicity
study in rats, the dose severely toxic to 10 % (STD10) of the
animals was 4.5 mg/kg which is equivalent to 27 mg/m2 body
surface area. One tenth of this rodent dose was not severely
toxic to dogs in the 3-cycle toxicity study in dogs. One tenth of
the STD10 in rats, 2.7 mg/m2, is equivalent to 4.3 mg per
patient (based on a body surface area of 1.6 m2 per patient).
Therefore, 4 mg was determined as the safe starting dose in
humans. Dose escalation occurred in steps of 100 % until the
observation of the first drug-related grade ≥2 adverse event
(AE) in cycle 1. Thereafter, doses of BI 831266 were intended
to be escalated in decreasing steps of 100 to 20 % (or, prior to
the protocol amendment dated July 20, 2009: ≤50 % until the
first DLT, and ≤35 % thereafter). Patients were treated for as
long as clinical benefit was derived. Treatment was terminated
if a DLT occurred which did not resolve to a degree that
allowed treatment continuation; if a second DLT occurred; if
there was an intolerable AE; if consent was withdrawn; or if a
treatment cycle was delayed for >2 weeks.
One protocol amendment was made during the study: the
dose escalations were changed from ‘100 % until the first
CTCAE grade ≥2, then ≤50 % until the first DLT, then
≤35 % thereafter’, to ‘100 % until the first DLT followed by
100 to 20 % thereafter, depending on the overall safety infor-
mation, including previous dose cohorts and cycles ≥2’. This
amendment was performed to make the dose escalation more
flexible and faster, and to reduce the number of patients
unnecessarily treated at low (and possibly sub-therapeutic)
doses of BI 831266 in the early part of the study. This was
supported by the safety data from the on-going phase 1 study
of the sister front-runner compound BI 811283 [12], which
was already recruiting patients at much higher doses (105 mg
in Schedule A) using the same treatment schedules as in this
study and a similar starting dose, with no significant safety
issues. The amendment also changed the criterion for starting
the 3-week treatment schedule from ‘the occurrence of the
first relevant drug-related AE’ to ‘the establishment of the
MTD in the 4-week schedule’. The reason for this amendment
was to reduce the overall number of patients treated in the
study, again based on the data from the ongoing phase 1 study
of the front-runner compound BI 811283, which was already
treatingmore patients than anticipated due to the unexpectedly
high number of dose steps in that study. Thus, it was decided
not to recruit patients into the 3-week schedule of BI 831266
until the MTD for the 4-week schedule had been established.
The primary endpoint of the trial was the MTD of BI
831266, administered as a 24-h continuous infusion in a 4-
week schedule. Secondary endpoints included incidence and
intensity of AEs; incidence of DLTs; the PK profile of BI
831266; progression-free survival (PFS); objective response
rate; and duration of response. Pharmacodynamic endpoints
included change from baseline in the percentage of epidermal
cells expressing phosphorylated histone H3 (pHH3) and plas-
ma concentrations of caspase-cleaved fragment of CK-18 and
AGP.
Definition of DLT
A DLT was defined as one of the following events occurring
during the first treatment cycle: a drug-related non-hemato-
logic toxicity grade ≥3 (except untreated nausea, vomiting, or
diarrhea); drug-related neutropenia lasting for ≥7 days or
febrile neutropenia grade 4; or drug-related thrombocytopenia
grade 4 or thrombocytopenia grade ≥3 with complications.
Assessments
Safety was assessed as incidence and intensity of AEs, using
Medical Dictionary for Regulatory Activities criteria and
graded according to CTCAE version 3.0. Changes in safety
tests, including vital signs (blood pressure and pulse rate were
evaluated every 2 h during infusion of BI 831266), echocar-
diograms, electrocardiograms, and laboratory tests, were also
assessed.
Objective tumor response was measured using CT and/or
MRI scans performed at baseline and at the end of every other
treatment course, and evaluated according to Response Eval-
uation Criteria in Solid Tumors (RECIST) version 1.0 [13].
The duration of overall response was measured from the time
at which the measurement criteria were met for complete
response or partial response (PR; whichever was recorded
first) until the first date that recurrent or progressive disease
(PD) was objectively documented. PFS was defined as the
duration of time from the start of treatment to the time of
progression or death.
Plasma samples for PK analysis were collected for the first
and second infusions of BI 831266 at the following times:
5 min before the start of the 24-h infusion and 01:00, 02:00,
04:00, 12:00, 20:00, 23:59 (just before the end of the infu-
sion), 24:15, 24:30, 25:00, 26:00, 28:00, 32:00, 48:00, 72:00,
and 168:00 h after the start of the infusion. Further samples
were obtained in subsequent treatment cycles up to cycle 6,
just prior to the start and the end of the infusion of BI 831266.
Urine samples were also obtained after the first and second
infusions of BI 831266 at 0–4 h, 4–12 h, 12–24 h, 24–48 h,
and 48–72 h after the start of infusion. Concentrations of BI
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831266 in plasma and urine were determined using a validated
high-performance liquid chromatography–tandem mass spec-
trometry assay (data on file, Boehringer Ingelheim). Quanti-
fication was performed using a weighted (1/x2) linear least-
squares regression analysis generated from calibration stan-
dards. For plasma samples, the lower limit of quantification
for BI 831266 was 0.2 nM and the assay had a linear range up
to 200 nM. For urine samples, the lower limit of quantification
for BI 831266 was 2.00 nM and the assay had a linear range
up to 2000 nM. The mean relative error of the quality control
samples was 0.6–2.8 % and the mean coefficient of variation
range was 5.2–5.9 %.
Histone H3 is a well characterized substrate of Aurora B,
and measurement of its phosphorylation on serine 10 may be
used as a pharmacodynamic biomarker of Aurora B inhibition
[14]. In a previous study (data on file, Boehringer Ingelheim)
[15] a method had been described that allowed parallel deter-
mination of the pHH3 content in skin biopsies using Western
Blot and immunohistochemistry analyses. This method was
included in this study to analyze patient’s skin biopsies, taken
before and after treatment, with the expectation that there
should be a reduction in pHH3 post-treatment. Epidermal
pHH3 expression was determined in skin biopsies obtained
during screening and on day 16 of the first 4-week treatment
cycle, as soon as possible (within 6 h) after the end of the
second infusion of BI 831266 at TARGOS Molecular Phar-
macology GmBH (Kassel, Germany). Forearm punch biop-
sies of 3–4 mm were fixed in formaldehyde prior to being
paraffin-embedded. Sections were stained for hematoxylin
and eosin to identify areas of well preserved, healthy epider-
mis. Automated immunohistochemical staining for pHH3was
performed (Benchmark XT, Ventana/Roche Tissue Diagnos-
tics, Basel, Switzerland), utilizing a standard Universal DAB
detection procedure. Sections were counterstained in hema-
toxylin II solution. The number of cells with nuclear staining
of pHH3 (intensity 3+) per mm of stratum germinativum was
counted, and the percentage decrease from baseline in pHH3+
cells/mm of epidermis with BI 831266 was calculated.
Caspase-cleaved fragment of CK-18 is a marker for tumor
cell apoptosis. A specific antibody (M30) recognizes a neo-
epitope of CK-18 generated during apoptosis. This marker for
apoptosis was investigated in an exploratory manner in this
study, with the expectation that it should rise following treat-
ment if the treatment causes tumor cell apoptosis. Caspase-
cleaved fragments of CK-18 were quantified in plasma sam-
ples obtained predose and at 48, 72, and 168 h after the first 2
infusions of BI 831266. Samples were also collected predose
and at 168 h post-dose up to cycle 6. Plasma concentrations of
caspase-cleaved CK-18 were determined using a validated
enzyme-linked immunosorbent assay (ELISA) at Nuvisan
GmbH (Neu-Ulm, Germany) and a monoclonal antibody
M30-Apoptosense® ELISA kit (Peviva AB, Bromma, Swe-
den). The assay method is a sandwich type immunoassay that
uses the monoclonal ‘M5’ capture antibody directed against
CK-18 and a horseradish peroxidase conjugated monoclonal
‘M30’ antibody directed against the CK-18 asparate 396 neo-
epitope.
BI 831266 showed a moderate binding to plasma proteins
in humans, dogs and rats that was independent of the BI
831266 concentration. BI 831266 is bound to human serum
albumin as well as to AGP. Binding to AGP was highly
dependent on the AGP concentration. Higher AGP led to
higher total exposures of BI 831266 in plasma. To explore
the relevance of this finding, AGP plasma levels were inves-
tigated in this study. AGP was quantified in plasma samples
obtained during the first 2 treatment cycles at the same time
points as those used for the PK analysis. Further samples were
obtained up to cycle 6, predose, and at 168 h post-dose. AGP
Table 1 Patient demographics and disease characteristics at baseline
Total patients
(N=25)








Type of cancer, n (%)
Colorectal 12 (48.0)
Pancreas 4 (16.0)
Liver and biliary tree 2 (8.0)
Sarcoma of soft tissue or bone 2 (8.0)
Bladder 1 (4.0)
Cervix, vagina, vulva 1 (4.0)
Kidney and ureter 1 (4.0)
Prostate 1 (4.0)
Unknown 1 (4.0)
Prior anticancer therapy, n (%)
Chemotherapya 24 (96.0)
≥3 chemotherapies 18 (72.0)
Surgery 25 (100.0)
Radiotherapy 7 (28.0)
Hormone therapyb 3 (12.0)
Immunotherapyb 5 (20.0)
Otherb 3 (12.0)
ECOG PS Eastern Cooperative Group performance status
a Patients had received up to 7 lines of prior chemotherapy for metastatic
disease
bData missing for n=2 patients
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concentrations were determined using a validated
immunoturbidimetric assay.
Statistical analyses
All statistical analyses were descriptive and exploratory in
nature. A single population was defined for the efficacy and
safety analyses, which included all patients who received at
least 1 dose of BI 831266. All treated patients were also
included in the PK analysis, but patients with PK data that
did not appear plausible, or those with insufficient data, were
excluded from PK analyses.
Results
Patient demographics and disposition
Of the 29 patients who were enrolled in this trial, 25 were
subsequently entered and treated with study medication be-
tween November 2008 and October 2010. The most frequent
tumor type was colorectal cancer (CRC; n=12, 48 %). All
patients had undergone prior surgery and all patients except
for 1 had received prior chemotherapy for metastatic disease.
Most patients were heavily pretreated, with 18 patients (72 %)
having received ≥3 lines of prior chemotherapy (Table 1).
Treatment exposure
Patient cohorts were treated with escalating doses of BI
831266: 4 mg (n=4), 8 mg (n=3), 16 mg (n=3), 32 mg
(n=3), 64 mg (n=5), and 130 mg (n=7). One patient who
received both the day 1 and day 15 infusions died while still
on treatment prior to the end of cycle 1 due to PD with multi-
organ failure, which was not considered to be drug-related;
this patient was therefore not evaluable for DLT. The median
number of cycles completed was 2 (minimum: 1 cycle; max-
imum: 14 cycles; Table 2). Twenty-four patients (96.0 %)
discontinued treatment because of PD.
DLTs, safety, and tolerability
Only 1 patient (treated with 130 mg BI 831266) experienced a
DLT: treatment-related grade 3 febrile neutropenia associated
with grade 3 reduction in white cell count in cycle 1 starting
on day 15 (second infusion). This patient had received 7 prior
lines of treatment. The second BI 831266 infusion was com-
pleted as planned and the patient’s fever resolved on day 17
following treatment with standard therapy, including
filgrastim. Blood counts recovered on day 18 and the patient
completed a second cycle of treatment at a reduced dose of
100 mg according to the protocol. There were no other DLTs
in the 130 mg cohort. The trial was terminated prematurely by
the sponsor without further dose escalation at this stage;
therefore, the MTD of BI 831266 in the 4-week treatment
schedule could not be determined. The rationale for terminat-
ing the trial is described in the Discussion.
Among 25 patients treated, 17 (68 %) patients experienced
treatment-related AEs. Across all treatment cycles the most
frequent treatment-related AEs were fatigue (20 %), neutro-
penia and alopecia (16 % each), and anemia, dry skin, and
nausea (12% each; Table 3).Most treatment-related AEs were
mild (grade 1/2), with higher grade treatment-related AEs
Table 2 Exposure to BI 831266
BI 831266 dose
4 mg 8 mg 16 mg 32 mg 64 mg 130 mg Total
Patients treated, n (%) 4 (100) 3 (100) 3 (100) 3 (100) 5 (100) 7 (100) 25 (100)
Number of cycles completeda, n (%)
1 0 2 (66.7) 0 0 1 (20) 2b (28.6) 5 (20)
2 3 (75) 0 3 (100) 2 (66.7) 2 (40) 4 (57.1) 14 (56)
3 0 1 (33.3) 0 0 0 0 1 (4)
4 0 0 0 0 1 (20) 1 (14.3) 2 (8)
6 1 (25) 0 0 0 0 0 1 (4)
10 0 0 0 0 1 (20) 0 1 (4)
14 0 0 0 1 (33.3) 0 0 1 (4)
Total exposure time (days)
Mean 90.5 56.0 65.0 181.0 104.4 57.0 87.6
Minimum, maximum 47, 185 37, 93 65, 65 64, 414 37, 289 23, 109 23, 414
aA cycle was defined as completed if the patient received both infusions of BI 831266
bOne patient received both the day 1 and day 15 infusions of BI 831266 but died before the end of cycle 1
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(grade 3/4) observed only at 130 mg, the highest dose admin-
istered. All treatment-related grade 3/4 AEs were hematologic
and included neutropenia (grade 3: n=2; grade 4: n=1),
anemia (grade 3: n=2), and febrile neutropenia (grade 3:
n=1; Table 3). The treatment-related grade 4 neutropenia
lasted less than 7 days and was not considered a DLT. More
hematologic AEs (neutropenia, anemia, thrombocytopenia,
febrile neutropenia) and alopecia were observed with
130 mg BI 831266 than with the lower doses. All 7 patients
treated with 130 mg BI 831266 experienced at least 1 drug-
related hematologic AE, whereas no patients treated at lower
doses (4–64 mg) experienced drug-related AEs. In addition,
drug-related alopecia was reported more frequently in the
130 mg dose group than in the lower dose groups (Table 3).
Serious AEs were reported in 15 patients (Table 4); 12 of
these patients required hospitalization, with prolonged hospi-
talization required for 6 patients, and 5 patients had serious
AEs resulting in death. One patient died as a result of renal and
hepatic failure (4 mg cohort), 1 died because of multi-organ
failure (32 mg cohort), and 3 died because of malignant
neoplasm progression (64 mg: n=2; 130 mg: n=1). None of
these fatal AEs were considered to be drug-related.
Treatment discontinuation occurred in only 1 patient (who
was treated at 130 mg). This patient suffered a grade 3 general
physical health deterioration, which was not drug-related, and
subsequent disease progression.
CTCAE grade 3 white blood cell count was reported in 3
patients in the 130mg dose group. There was no trend towards
reduction of leucocytes or neutrophils over the treatment
period.
Pharmacokinetics
The PK characteristics of BI 831266 during cycle 1 are
summarized in Table 5. Plasma concentrations of BI 831266
generally increased during the 24-h infusion of each dose on
Table 3 Treatment-related AEs occurring in any patient (total number of patients treated N=25)
Treatment-related AEs in all patients
BI 831266 dose cohort 4 mg 8 mg 16 mg 32 mg 64 mg 130 mg Total





























Total number of patients
with treatment-related AE
1 0 2 0 3 0 2 0 2 0 7 5 17 (68) 5 (20)
Fatigue – – 1 – – – 1 – 1 – 2 – 5 (20) –
Neutropenia – – – – – – – – – – 4 3 4 (16) 3 (12)
Alopecia – – – – – – 1 – – – 3 – 4 (16) -
Anemia – – – – – – – – – – 3 2 3 (12) 2 (8)
Dry skin 1 – – – – – – – 1 – 1 – 3 (12) –
Nausea – – 1 – 1 – – – – – 1 – 3 (12) –
Thrombocytopenia – – – – – – – – – – 2 – 2 (8) –
Abdominal pain – – 1 – – – – – – – 1 – 2 (8) –
Myalgia – – 1 – – – – – – – 1 – 2 (8) –
Febrile neutropenia – – – – – – – – – – 1 1a 1 (4) 1 (4)
Stomatitis – – – – – – – – – – 1 – 1 (4) –
Pyrexia – – – – – – – – – – 1b – 1 (4) –
Arthralgia – – – – – – – – – – 1 – 1 (4) –
Dysgeusia – – – – – – – – – – 1 – 1 (4) –
Paresthesia – – – – – – 1 – – – – – 1 (4) –
Change of bowel habit – – – – 1 – – – – – – – 1 (4) –
Gynecomastia – – – 1 – – – – – – – 1 (4) –
Abdominal discomfort – – 1 – – – – – – – – – 1 (4) –
Abdominal pain lower – – 1 – – – – – – – – – 1 (4) –
Scratch – – 1 – – – – – – – – – 1 (4) –
AE adverse event; DLT dose-limiting toxicity
a DLT
b Treatment-related serious AE
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day 1 or day 15; there was a slight increase of the first 4 dose
levels until 4–20 h after the start of the infusion. Time from
dosing to maximum measured concentration (tmax) was
reached at ~20 h after the start of the infusion. After the
infusion was stopped, plasma concentrations of BI 831266
declined in a biphasic fashion, with an initial rapid decline
followed by a much slower elimination phase (BI 831266
plasma concentration-time profiles are shown in Fig. 1). The
geometric mean terminal elimination half-life ranged from 15
to 39 h after the first dose and from 14 to 29 h after the second
dose. As a consequence of high variability in the BI 831266
exposure profiles, dose proportionality could not be deter-
mined. Ten PK profiles did not appear plausible, since plasma
concentrations rose and declined extremely rapidly (data not
shown). In all treatment groups, the amount of BI 831266
excreted in urine accounted for <15 % of the dose, indicating
urinary excretion is a minor pathway of elimination, and
nearly all of the BI 831266 that would have been excreted in
urine was eliminated within 72 h.
Pharmacodynamics
Twenty-two (88 %) patients were evaluable for analysis of the
change in pHH3 expression in skin biopsies (4 mg: n=3/4;
8 mg, 16 mg, 32 mg: n=3/3 each; 64 mg: n=4/5; 130 mg:
n=6/7) and analysis of the change in plasma concentrations of
caspase-cleaved CK-18 and AGP (4 mg: n=4/4; 8 mg: n=2/3;
16mg, 32mg, 64mg: n=3/3 each; 130 mg: n=7/7). Mean and
individual percentage changes in epidermal cells/mm positive
for pHH3 from baseline to post-treatment with BI 831266 are
shown in Fig. 2a. There was a general trend towards a de-
crease in pHH3with increasing doses of BI 831266. However,
high interpatient variability was observed at all doses, except
the 130 mg dose. At this dose, there was a mean reduction of
71.6 % (standard deviation, 4.5) in the number of pHH3+
cells/mm, and this reduction was consistent and robust. Im-
munohistochemical staining images for pHH3 at baseline and
post-treatment at cycle 1 day 16 are shown in Fig. 2b for a
patient with cervical cancer treated with 32 mg BI 831266 and
who had a PR (described below). Each individual patient’s
percentage decrease was plotted against the patient’s PK area
under the concentration-time curve (AUC) for the dose at
which the skin biopsy sample was taken. This did not show
an apparent relationship between percentage decrease and
drug exposure.
Plasma concentrations of caspase-cleaved CK-18 showed
variability and no consistent association with the dose of BI
831266 (Fig. 3a).
It has been reported that the exposures of some com-
pounds are related to the concentration of AGP in patients
[16, 17]. Therefore, BI 831266 dose-normalized AUC0-∞
exposure was plotted against the overall AGP exposure
assessed as the area under the effect curve to the last
evaluable time point (AUEC0-tz), excluding AUC0-∞ values
from patients with abnormal PK profiles (Fig. 3b). Although
the patient with the highest AGP concentrations also had the
highest BI 831266 AUC0-∞, the overall data showed no trend
of BI 831266 exposure with AGP concentration.
Antitumor activity
One patient (4.0%) with cervical cancer, whowas treated with
32 mg BI 831266, experienced a confirmed PR according to
RECIST, with a duration of 141 days and PFS of 414 days.
The patient initially experienced stable disease (SD) during
the first 9 cycles, and was first documented to have a PR after
cycle 10. The patient completed a total of 14 cycles and
remained in PR but stopped treatment due to serious AEs of
gangrene and multi-organ failure.
CT scans showing tumor shrinkage in this patient are
shown in Fig. 4. An additional 4 patients (16.0 %; colorectal
cancer: n=2; pancreatic cancer: n=1; bladder cancer: n=1)
experienced SD according to RECIST as best response. PFS
among these patients ranged from 78 to 274 days. PFS in the
20 patients (80.0 %) without an objective RECIST response or
SD ranged from 21 to 94 days.
The serious AEs observed in this one patient with PR were
not considered to be treatment-related. The patient had suf-
fered from hypercoagulability even before entering the
Table 4 All-causality serious AEs occurring in any patient
BI 831266 dose (mg) Serious AE per patient




32 Gangrene, deep vein thrombosis, chest pain,
multi-organ failurea
32 Fatigue
64 Catheter site infection, dyspnea, malignant
neoplasm progressiona
64 Infection




130 Dyspnea, general physical health deterioration,
malignant neoplasm progressiona




a Serious AE resulting in death
b Considered by the investigators to be related to trial medication
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clinical trial with BI 831266. The patient had had pulmo-
nary embolization more than 1 month before the first drug
application with BI 831266. After initial heparinization, the
patient received oral anticoagulation with phenprocoumon.
Nevertheless, the patient developed a massive thrombosis
of the entire left lower extremity that extended to the pelvis,
representing a 3-level thrombosis and also a partial throm-
bosis of the right posterior tibial vein. Despite recom-
mencement of low molecular weight heparinization, the
patient developed a gangrene of the left lower extremity,
presenting as phlegmasia coerulea dolens, which necessi-
tated the amputation of the left lower extremity that resulted
in death due to multi-organ failure.
Discussion
This study was discontinued prematurely primarily for two
reasons: firstly, a lack of objective responses demonstrated by
a sister front-runner compound developed by Boehringer
Ingelheim (BI 811283), another intravenously-administered
Aurora kinase B inhibitor [12, 18]. In a phase 1 study of BI
811283 involving a study population similar to the present
study (121 patients with a variety of solid malignancies), no
objective responses were seen and SD was only achieved in a
third of the patients. Secondly, a new oral Aurora kinase
inhibitor was being developed that would offer significantly
improved convenience for patients [19] compared with the
mode of administration of BI 831266 and BI 811283, which
had to be administered via a 24-h continuous infusion through
a central line.
Although reaching clinical activity in the form of responses
does not typically represent a primary objective of a phase 1
trial, the fact that only 1 out of 25 patients experienced an
objective response of the level of a PR let us examine the
entire test assumption. In order to find out whether the antic-
ipated mode of action of the drug and member of that class of
drugs, respectively, was accurate, the measurement of histone
H3 phosphorylated on serine 10, a well characterized substrate
of Aurora kinase B, was performed. Pharmacodynamic anal-
yses of skin biopsy samples demonstrated a reduction of
pHH3 following treatment in some patients, suggesting that
there was evidence of Aurora kinase inhibition. Analysis of
the epidermal expression of the mitosis marker pHH3 as an
indicator of Aurora kinase B inhibition assumes that BI
Table 5 Non-compartmental PK parameters (geometric means±geometric coefficients of variation, unless otherwise stated) for the first and second
infusions of BI 831266
4 mg (n=4) 8 mg (n=3) 16 mg (n=3) 32 mg (n=3) 64 mg (n=5) 130 mg (n=7)
Cycle 1, day 1
Cmax (nmol/L) 5.84±53 22.0±72 88.2±582 126±43 3310±4080 923±1610
Cmax, norm (nmol/L) 1.46±53 2.75±72 5.51±582 3.92±43 51.7±4080 7.10±1610
tmax (hours)
a 20.4 (20–24) 23.6 (20–24) 20.0 (2.0–21) 24.3 (20–25) 20.0 (20–48) 20.1 (1.0–22)
CL (mL/min) 858±66 531±42 410±138 544±15 50.4±660 311±307
AUC0–24 (nmol hours/L) 98.7±64 359±35 928±155 1430±18 29,300±1540 10,400±371
AUC0–∞ (nmol hours/L) 147±66 475±42 1230±138 1860±15 40,100±660 13,200±307
AUC0–∞, norm (nmol hours/L) 36.8±66 59.4±42 77.0±138 58.0±159 626±660 102±307
t1/2 (hours) 19.6±71 14.5±18 21.0±59 16.9±64 39.0±30 24.1±42
Cycle 1, day 15
Cmax (nmol/L) 6.89±16 – 280±220,000 600±71,200 1260±2600 1080±1370
Cmax, norm (nmol/L) 1.72±16 – 17.5±220,000 18.8±71,200 19.6±2600 8.31±1370
tmax (hours)
a 20.1 (20–21) – 20.0 (1.0–21) 20.0 (12–21) 19.1 (12–24) 20.2 (20–24)
CL (mL/min) 649±22 – 219±582 118±4810 109±949 386±245
AUC0–24 (nmol hours/L) 119±6.5 – 1760±898 7200±7270 13,200±1810 13,200±540
AUC0–∞ (nmol hours/L) 194±22 – 2300±582 8540±4810 18,500±949 10,600±245
AUC0–∞, norm (nmol hours/L) 48.6±22 – 144±582 267±4810 289±949 81.9±245
t1/2 (hours) 23.8±108 – 24.2±40 13.8±6.3 26.1±25 29.0±65.3
aMedian (minimum, maximum)
–Insufficient data to calculate descriptive statistics
AUC0–24 area under the plasma concentration–time curve over the time interval from 0 to 24 h after the start of infusion; AUC0–∞ area under the plasma
concentration–time curve over the time interval from 0 extrapolated to infinity; CL total clearance of analyte in plasma after intravenous administration;
Cmaxmaximummeasured concentration; norm dose normalized; PK pharmacokinetic; t1/2 terminal half-life; tmax time from dosing to maximummeasured
concentration
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831266, at a dose of 130 mg, is biologically active, with an
antimitotic mechanism of action. A consistent and robust
reduction of approximately 70 % from baseline was observed
in the number of epidermal cells expressing pHH3 from skin
biopsies in all 6 evaluable patients treated at 130 mg BI
831266. However, a dose relationship was not clear; this is
partly due to interpatient variability in pHH3 expression in
some dose cohorts which precludes a conclusive observation.
The decrease in the number of pHH3+ cells observed at the
highest dose level of BI 831266 was consistent with selective
Aurora kinase B inhibitory activity, which has been observed
previously with other Aurora kinase B inhibitors in preclinical
studies (data on file, Boehringer Ingelheim) [20–24]. We have
therefore demonstrated the mechanism of action of BI 831266
in this trial. However, due to the small number of responders
in this study, an exploratory analysis to determine a correlation
between pHH3 and clinical outcome was not possible. There-
fore, proof of principle in terms of sufficient Aurora kinase B
inhibition leading to corresponding tumor shrinkage could not
be proved in this trial.
A next step in the cascade of necessary proofs is the one of
the mode of action-based consequent proof of a biologic effect
downstream of the triggered initial drug target. As such,
Aurora kinase B-induced apoptosis was investigated. Plasma
concentrations of caspase-cleaved CK-18, a marker of apo-
ptosis [25, 26], were highly variable and did not appear to be
Fig. 1 Mean plasma concentration-time profiles of BI 831266 on a day 1
and b day 15 of cycle 1 after 24-h infusion of 4, 8, 16, 32, 64 and 130 mg
BI 831266. Footnote: Concentration-time data could only be evaluated
for 2 out of 3 patients in the 8 mg cohort on day 15, therefore standard
deviation values could not be calculated
Fig. 2 a Individual and mean decrease in the number of pHH3+ cells at
sc reening and af te r infus ion of BI 831266 by dose . b
Immunohistochemical staining for pHH3 at baseline (top) and post-
treatment (bottom) on cycle 1 day 16 in a patient with cervical cancer
who experienced a confirmed PR. pHH3 phosphorylated histone H3, PR
partial response
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related to exposure to BI 831266. This result does not indicate
that BI 831266 is substantially active. In this context, it has to
be admitted that the molecular pathways through which tumor
cells undergo cell death in response to mitotic arrest are not
well defined. Whereas apoptosis, which is observed with
many antimitotic agents, is a process well characterized by
the activation of caspases, an alternative mechanism of cell
death, termed mitotic catastrophe, is much less elucidated
[27].
In order to exclude the possibility that this lack of activity
was, at least in part, also the efflux of variability or insuffi-
ciency of exposure of tumor cells to the BI 831266, detailed
PK investigations were undertaken. Plasma PK profiles
showed extremely high variability, reflected in exposure pa-
rameters during the infusion, with some patients having much
higher maximum measured concentration (Cmax) and AUC
values than others. Therefore, dose proportionality could not
be determined. Ten concentration-time PK profiles, rising and
declining extremely rapidly, were incompatible with what was
to be expected. This type of profile is not typically observed,
even in drug-drug interaction trials. Drug-drug interactions
may change the magnitude of a PK profile, but they usually
do not change the basic shape of a profile in this manner. The
reason for these profiles could not be established from the
available data. Without these profiles, dose-normalized
AUC0-∞ and Cmax values appeared independent of dose (data
not shown), suggesting that the increase in exposure was near
linear at least, when the 64 mg dose level was excluded.
However, the high variability and exclusion of the PK profiles
preclude any definitive conclusions being drawn, especially
with regard to correlation between PK and efficacy. Preclini-
cal efficacy studies using various tumor models have shown
that a target steady-state concentration of BI 831266 required
to reach full antitumor activity was 80–153 nM, depending on
the tumor model (data on file, Boehringer Ingelheim). In this
phase 1 study, the geometric mean Cmax at steady state of the
16 mg dose cohort was 280 nmol/L, which is already above
the target exposure based on preclinical models. Due to high
variability in PK parameter values, but nonetheless also due to
the restricted clinical activity, conclusions about PK correla-
tion with efficacy could not be established.
In contrast thereto, an assessment of the safety data from
the present trial revealed a dose effect for BI 831266. Patients
who received the highest dose tested in this trial (130 mg BI
831266) experienced treatment-related hematologic AEs,
which were not observed in patients treated at lower dose
levels. Treatment-related alopecia was also reported more
frequently in the 130 mg BI 831266 cohort than at lower
doses.
One PRwas reported in this study, with SD seen in 16% of
patients. This is consistent with data from the phase 1 studies
of other Aurora kinase inhibitors, most of which are inhibitors
of Aurora kinase A, B, or all 3 mitotic kinases; SD was the
best response in the majority of these studies [28–35]. Only 2
Aurora kinase inhibitors have reported a PR in their phase 1
studies [28, 30]; 1 of these was with the use of granulocyte
colony-stimulating factor which allowed a higher dose of the
compound to be administered [30]. Hematologic toxicity, an
expected class effect, was a common DLT in all of these
studies, preventing further dose escalation. To date, the most
prominent efficacy of an Aurora kinase inhibitor has been
observed in hematologic malignancies, specifically in acute
myeloid leukemia where a superior objective clinical response
rate was seen with barasertib treatment compared with low-
dose cytosine arabinoside treatment in the control arm [36].
This leads to the fundamental open question of whether
overall this class of compounds is sufficiently attractive and
different from other already existing drugs to be further
Fig. 3 a Individual and mean maximum percentage increase in caspase-
cleaved CK-18 plasma concentrations from baseline after the first 2 infu-
sions of BI 831266. b Individual dose-normalized BI 831266 AUC0-∞
versus AGP AUEC0-tz, excluding abnormal PK profiles. CK-18
cytokeratin-18, AGP alpha-1-acid glycoprotein, AUC0-∞ area under the
plasma concentration–time curve over the time interval from 0 extrapolated
to infinity, AUEC0-tz area under the effect curve to the last evaluable
timepoint, PK pharmacokinetic
418 Invest New Drugs (2015) 33:409–422
developed and in case of affirmation, which of the represen-
tatives should be selected and how they should be further
developed.
Antimitotic therapies such as vinca alkaloids, taxanes, or
even epothilones directed against tubulin and its homeostasis
are known as highly effective compounds. Various substances
mainly interfering with distinct functions in the mitotic pro-
cess belong to different druggable target classes such as mi-
totic kinesins, polo-like kinases, and Aurora kinases [27]. No
patient selection based on the molecular characterization has
been accomplished to-date. This may be on one hand due to
the assumption that increased mitosis is an ubiquitous phe-
nomenon in all cancer populations, although not substantiated
by data [37], and on the other hand that we do not know yet
which tumors are likely to respond to a particular targeted
inhibitor ofmitosis due to our incomplete understanding of the
respective downstream mechanisms. So, for example, it is
unclear whether response to Aurora kinase inhibition depends
on the p53 status of these tumors [38].
As with most therapeutic scenarios in oncology, particular-
ly in solid tumors, the combination of drugs has proven to be
more effective than monotherapy. Since Aurora kinase B
Fig. 4 CT scans of a patient with cervical cancer who experienced a confirmed PR. a and b: baseline scans; c and d: following 14 cycles of treatment
with BI 831266. PR was first documented after cycle 10. PR partial response
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specifically regulates the spindle checkpoint, combination
with substances that target the mitotic spindle and that depend
on the spindle checkpoint for activity (such as taxanes) could
have been interesting to evaluate [39]. The combination with
substances that require exposure during other phases of the
cell cycle may represent an advantage, since distinct from
traditional antimitotic agents Aurora B inhibitors do not arrest
cells in mitosis, but let them continue to cycle. Combining
Aurora B inhibition with Aurora A inhibition could therefore
be considered in principle. However, an example of lack of
efficacy of simultaneously targeting both enzymes has been
demonstrated on pancreatic cancer cells [40]. Increased inhi-
bition of Aurora kinase B activity with barasertib in combi-
nation with irinotecan and gemcitabine in a sequence-
dependent manner (with barasertib before chemotherapy)
and increased induction of apoptosis has been demonstrated
in colorectal and pancreatic cell lines [41, 42]. It is a matter of
speculation whether potentiation may be possible at doses
below those inducing limiting neutropenia.
The very limited clinical activity observed in our trial
compares well to the overall modest clinical activity of other
Aurora kinase B inhibitors. This limitation is not even restrict-
ed to the entire family of Aurora kinase inhibitors but can be
identified as a general feature of all inhibitors targeting the
process of mitosis, including kinesins, and polo-like kinases
[43–45]. This leads to the fundamental question of whether
the basic theorem that tumors are characterized by short
doubling times and high proliferation rate is correct. Although
a plethora of preclinical data represent the basis of that belief,
insight in patient data in comparison reveal the opposite [37].
Whereas the means and medians of tumor doubling times for
five of the most prevalent cancer entities are accumulating at
about 5 days, the results for patient data vary from about 100
to 400 days. The fact that obviously only a very small sub-
fraction (<1 %) of solid tumors are undergoing mitosis seems
to be a rather simple explanation of why compounds interfer-
ing with the mitotic process are generally so ineffective.
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